Eszter Szalai1, Jill R Wells1, Laura Ward2, Hans E Grossniklaus3. 1. Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. 2. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Pathology, Emory University School of Medicine, Atlanta, Georgia. Electronic address: ophtheg@emory.edu.
Abstract
PURPOSE: To examine the BRCA1-associated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to analyze the correlation between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features. DESIGN: Retrospective case series. PARTICIPANTS: Forty patients with uveal melanoma (mean age, 57.98±14.75 years) were included in this analysis, of whom 20 had no metastatic disease and 20 had metastasis. METHODS: Medical records and histology slides of patients with primary uveal melanoma treated by enucleation were reviewed. BAP1 expression was evaluated by immunohistochemical staining of formalin-fixed, paraffin-embedded sections. Immunoreactivity in the nucleus and cytoplasm were graded by estimating the percentage of primary tumor cells showing a positive staining of their nucleus or cytoplasm per 1 high-power field 200× (grades 0-3). MAIN OUTCOME MEASURES: Tumor size, histologic features, nuclear and cytoplasmic BAP1 immunoreactivity grade, and patient outcome, including development of metastasis. RESULTS: Significantly lower (P = 0.025) nuclear BAP1 immunoreactivity was observed in the metastatic melanoma group. Greater tumor thickness, basal diameter, and more advanced TNM stage were associated with an increased odds ratio of developing metastasis (P < 0.05). In addition, tumors with a higher proportion of cells expressing nuclear BAP1 had decreased odds of developing metastatic disease in a multivariate model (P = 0.042). Metastasis-free survival was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004). CONCLUSIONS: Time to metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 immunoreactivity. Nuclear BAP1 stain is the only significant independent predictor of metastatic disease in this study. Our data support the role of BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.
PURPOSE: To examine the BRCA1-associated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to analyze the correlation between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features. DESIGN: Retrospective case series. PARTICIPANTS: Forty patients with uveal melanoma (mean age, 57.98±14.75 years) were included in this analysis, of whom 20 had no metastatic disease and 20 had metastasis. METHODS: Medical records and histology slides of patients with primary uveal melanoma treated by enucleation were reviewed. BAP1 expression was evaluated by immunohistochemical staining of formalin-fixed, paraffin-embedded sections. Immunoreactivity in the nucleus and cytoplasm were graded by estimating the percentage of primary tumor cells showing a positive staining of their nucleus or cytoplasm per 1 high-power field 200× (grades 0-3). MAIN OUTCOME MEASURES: Tumor size, histologic features, nuclear and cytoplasmic BAP1 immunoreactivity grade, and patient outcome, including development of metastasis. RESULTS: Significantly lower (P = 0.025) nuclear BAP1 immunoreactivity was observed in the metastatic melanoma group. Greater tumor thickness, basal diameter, and more advanced TNM stage were associated with an increased odds ratio of developing metastasis (P < 0.05). In addition, tumors with a higher proportion of cells expressing nuclear BAP1 had decreased odds of developing metastatic disease in a multivariate model (P = 0.042). Metastasis-free survival was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004). CONCLUSIONS: Time to metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 immunoreactivity. Nuclear BAP1 stain is the only significant independent predictor of metastatic disease in this study. Our data support the role of BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.
Authors: Mrinali P Gupta; Anne Marie Lane; Margaret M DeAngelis; Katie Mayne; Margaux Crabtree; Evangelos S Gragoudas; Ivana K Kim Journal: JAMA Ophthalmol Date: 2015-08 Impact factor: 7.389
Authors: J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock Journal: Science Date: 2010-11-04 Impact factor: 47.728
Authors: Colleen M Cebulla; Elaine M Binkley; Robert Pilarski; James B Massengill; Karan Rai; David A Liebner; Meghan J Marino; Arun D Singh; Mohamed H Abdel-Rahman Journal: Ophthalmic Genet Date: 2015-02-17 Impact factor: 1.803
Authors: Johannes A P van de Nes; Jasmin Nelles; Stefan Kreis; Claudia H D Metz; Thomas Hager; Dietmar R Lohmann; Michael Zeschnigk Journal: Am J Surg Pathol Date: 2016-06 Impact factor: 6.394
Authors: Richard W Joseph; Payal Kapur; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; Thai Ho; John C Cheville; Eugene Frenkel; Dinesh Rakheja; James Brugarolas; Alexander Parker Journal: Cancer Date: 2013-12-30 Impact factor: 6.860
Authors: Marcel Martin; Lars Maßhöfer; Petra Temming; Sven Rahmann; Claudia Metz; Norbert Bornfeld; Johannes van de Nes; Ludger Klein-Hitpass; Alan G Hinnebusch; Bernhard Horsthemke; Dietmar R Lohmann; Michael Zeschnigk Journal: Nat Genet Date: 2013-06-23 Impact factor: 38.330
Authors: Christina L Decatur; Erin Ong; Nisha Garg; Hima Anbunathan; Anne M Bowcock; Matthew G Field; J William Harbour Journal: JAMA Ophthalmol Date: 2016-07-01 Impact factor: 7.389
Authors: Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour Journal: Invest Ophthalmol Vis Sci Date: 2008-08-21 Impact factor: 4.799
Authors: Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus Journal: JAMA Ophthalmol Date: 2018-10-01 Impact factor: 7.389
Authors: Carmen Baumann; Danilo Iannetta; Sarah E Coupland; Carl Groenewald; Mandagere Vishwanath; Heinrich Heimann Journal: Ocul Oncol Pathol Date: 2019-12-05
Authors: Gustav Stålhammar; Thonnie Rose O See; Stephen Phillips; Stefan Seregard; Hans E Grossniklaus Journal: Transl Vis Sci Technol Date: 2019-05-06 Impact factor: 3.283